Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246149 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Tebentafusp in High Risk Ocular Melanoma
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
NCT06246149: Recruiting Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
NCT06246149 is a Phase 3 study that is actively recruiting participants, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 290 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06246149, a Phase 3 study, is actively recruiting participants, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
Study Summary
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Primary Outcome
RFS is defined as the time between randomization and local recurrence, distant recurrence, or death, whichever occurs first
Interventions
- DRUG Tebentafusp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2032-11 |
| Phase | Phase 3 |
What NCT06246149 shows while recruiting
NCT06246149 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Tebentafusp is the first listed.
NCT06246149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06246149 about?
NCT06246149 is a clinical study titled "Adjuvant Tebentafusp in High Risk Ocular Melanoma". At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastat...
What is the current status of trial NCT06246149?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2024-11-11. Estimated completion is 2032-11.
What interventions are being tested in trial NCT06246149?
The interventions under investigation include: Tebentafusp (DRUG).
Who is sponsoring clinical trial NCT06246149?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06246149's enrollment target sits among peer trials
290 1171st of 2000 higher than 828 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI